Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model

BACKGROUND: Patients with hemophilia have deficiencies in intrinsic coagulation factors and can develop inhibitors that limit the effectiveness of replacement coagulation factors. Marstacimab, a human monoclonal antibody, binds and inhibits the human tissue factor pathway inhibitor. Marstacimab is c...

Descripción completa

Detalles Bibliográficos
Autores principales: Pittman, Debra D., Rakhe, Swapnil, Bowley, Sheryl R., Jasuja, Reema, Barakat, Amey, Murphy, John E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8925002/
https://www.ncbi.nlm.nih.gov/pubmed/35316941
http://dx.doi.org/10.1002/rth2.12679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8925002/
https://www.ncbi.nlm.nih.gov/pubmed/35316941
http://dx.doi.org/10.1002/rth2.12679

Ejemplares similares